Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang, Hashem B. El–Serag, Rohit Loomba
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 4, pp. 223-238
Open Access | Times Cited: 1344

Showing 1-25 of 1344 citing articles:

Global burden of liver disease: 2023 update
Harshad Devarbhavi, Sumeet K. Asrani, Juan Pablo Arab, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 516-537
Open Access | Times Cited: 876
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Chen Yang, Hailin Zhang, Linmeng Zhang, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 20, Iss. 4, pp. 203-222
Closed Access | Times Cited: 442
Global epidemiology of cirrhosis — aetiology, trends and predictions
Daniel Q. Huang, Norah A. Terrault, Frank Tacke, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 388-398
Open Access | Times Cited: 393
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer
Daniel Q. Huang, Amit G. Singal, Yuko Kono, et al.
Cell Metabolism (2022) Vol. 34, Iss. 7, pp. 969-977.e2
Open Access | Times Cited: 342
Management of Hepatocellular Carcinoma
Zachary J. Brown, Diamantis I. Tsilimigras, Samantha M. Ruff, et al.
JAMA Surgery (2023) Vol. 158, Iss. 4, pp. 410-410
Closed Access | Times Cited: 341
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 303
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Ming Ren Toh, Evelyn Wong, Sunny H. Wong, et al.
Gastroenterology (2023) Vol. 164, Iss. 5, pp. 766-782
Closed Access | Times Cited: 290
Autophagy in liver diseases: A review
Hui Qian, Xiaojuan Chao, Jessica A. Williams, et al.
Molecular Aspects of Medicine (2021) Vol. 82, pp. 100973-100973
Open Access | Times Cited: 250
Changing epidemiology of hepatocellular carcinoma in Asia
Chenhao Zhang, Yifei Cheng, Shu Zhang, et al.
Liver International (2022) Vol. 42, Iss. 9, pp. 2029-2041
Closed Access | Times Cited: 241
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
Darren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 4, pp. 521-530
Open Access | Times Cited: 217
Non-alcoholic fatty liver disease: A patient guideline
Sven Francque, Giulio Marchesini, Achim Kautz, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100322-100322
Open Access | Times Cited: 208
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 203
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
Stephen A. Harrison, Rebecca Taub, Guy Neff, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2919-2928
Open Access | Times Cited: 201
Current epidemiology in hepatocellular carcinoma
Peter Konyn, Aijaz Ahmed, Donghee Kim
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 11, pp. 1295-1307
Closed Access | Times Cited: 200
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
Friedrich Foerster, Simon Johannes Gairing, Lukáš Müller, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 446-457
Open Access | Times Cited: 199
Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 199
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 8, pp. 487-503
Closed Access | Times Cited: 191
An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD
Grace En Hui Lim, Ansel Shao Pin Tang, Cheng Han Ng, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 21, Iss. 3, pp. 619-629.e7
Open Access | Times Cited: 187
Metabolic adaptation of lymphocytes in immunity and disease
Nicole M. Chapman, Hongbo Chi
Immunity (2022) Vol. 55, Iss. 1, pp. 14-30
Open Access | Times Cited: 187
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
Roser Pinyol, Sara Torrecilla, Huan Wang, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 865-878
Open Access | Times Cited: 178
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 61-116
Open Access | Times Cited: 171
β-Catenin signaling in hepatocellular carcinoma
Chuanrui Xu, Zhong Xu, Yi Zhang, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 4
Open Access | Times Cited: 171
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression
Lorenzo A. Orci, Marco Sanduzzi‐Zamparelli, Berta Caballol, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 2, pp. 283-292.e10
Open Access | Times Cited: 162
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach
Tsubasa Tsutsumi, Mohammed Eslam, Takumi Kawaguchi, et al.
Hepatology Research (2021) Vol. 51, Iss. 11, pp. 1115-1128
Closed Access | Times Cited: 154
Page 1 - Next Page

Scroll to top